Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Aortic stenosis is fairly uncommon among young people, though not absent. In younger folks, the disease is typically caused by a congenital heart condition. As we age, calcium deposits can build up ...

A high burden of heart valve diseases is driving its expansion. India’s transcatheter aortic valve replacement (TAVR) market ...

The last two decades have seen an increase in the use of biological over mechanical heart valve replacements. However, while ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research led by the University of Bristol ...

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research has found.

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.